Author

Xu-Hong Min

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Benmelstobart With or Without Anlotinib After Chemoradiotherapy for Unresectable Non-Small Cell Lung Cancer: The R-ALPS Randomized Clinical Trial.

This randomized clinical trial found that benmelstobart with or without anlotinib significantly improved progression-free survival (PFS) compared with placebo and adding anlotinib did not significantly improve PFS compared with benmelstobart alone and increased severe and fatal treatment-related adverse events.

Yong-Ling Ji, Qi-Wen Li, Long Chen et al. · JAMA Oncology · 0 citations

Clinical trial Open access Aug 2026

Safety and efficacy of first-line iparomlimab and tuvonralimab (QL1706) plus carboplatin and etoposide in patients with extensive-stage small cell lung cancer: an open-label, single-arm, phase 2 trial (DUBHE-L-209)

Background Iparomlimab and tuvonralimab (QL1706) is a MabPair product consisting of PD-1 and CTLA-4 monoclonal antibodies. This single-arm, multicenter, phase 2 study assessed the safety and efficacy of first-line QL1706 plus etoposide and carboplatin (EC) for extensive-stage small cell lung cancer (ES-SCLC). Methods P...

Yun Fan, Run-Xiang Yang, Xu-Hong Min et al. · Frontiers in Immunology · 0 citations